Joseph Paul Eder, MD

• Ian Odell
• Jill Lacy
• Joanna Gibson
• Jonathan Leventhal
• Karin Finberg
• Michael Cecchini
• Patricia LoRusso
• Peter M. Glazer
• Roy S. Herbst
• Ryan B. Jensen
• Zenta Walther

Signal Transduction; Clinical Trial; Clinical Trial, Phase I; Precision Medicine

• BRCA2 BRC missense variants disrupt RAD51-dependent DNA repairJimenez-Sainz J, Mathew J, Moore G, Lahiri S, Garbarino J, Eder JP, Rothenberg E, Jensen RB. BRCA2 BRC missense variants disrupt RAD51-dependent DNA repair. ELife 2022, 11: e79183. PMID: 36098506, PMCID: PMC9545528, DOI: 10.7554/elife.79183.
• Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose EscalationAtrafi F, Boix O, Subbiah V, Diamond JR, Chawla SP, Tolcher AW, LoRusso PM, Eder JP, Gutierrez M, Sankhala K, Rajagopalan P, Genvresse I, Langer S, Mathijssen RHJ, Verweij J, Bruns I, Lolkema MP. Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation. Clinical Cancer Research 2022, 28: 2969-2969. PMID: 35775194, DOI: 10.1158/1078-0432.ccr-22-1792.
• Reply to E. Rosenbaum et alEder JP. Reply to E. Rosenbaum et al. JCO Precision Oncology 2022, 6: e2200136. PMID: 35675573, PMCID: PMC9200392, DOI: 10.1200/po.22.00136.
• Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockadeGomez-Roca C, Cassier P, Zamarin D, Machiels JP, Gracia J, Hodi F, Taus A, Garcia M, Boni V, Eder JP, Hafez N, Sullivan R, Mcdermott D, Champiat S, Aspeslagh S, Terret C, Jegg AM, Jacob W, Cannarile MA, Ries C, Korski K, Michielin F, Christen R, Babitzki G, Watson C, Meneses-Lorente G, Weisser M, Rüttinger D, Delord JP, Marabelle A. Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade. Journal For ImmunoTherapy Of Cancer 2022, 10: e004076. PMID: 35577503, PMCID: PMC9114963, DOI: 10.1136/jitc-2021-004076.
• Yale Precision Medicine Tumor Board: reawakening the guardian of the genomeGrant MJ, Finberg KE, Walther Z, Stein SM, Lacy J, Eder JP, Goldberg SB. Yale Precision Medicine Tumor Board: reawakening the guardian of the genome. The Lancet Oncology 2022, 23: 337-338. PMID: 35240081, DOI: 10.1016/s1470-2045(22)00037-7.
• Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinomaHaddad RI, Seiwert TY, Chow LQM, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Albright A, Mogg R, Ayers M, Huang L, Lunceford J, Cristescu R, Cheng J, Mehra R. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. Journal For ImmunoTherapy Of Cancer 2022, 10: e003026. PMID: 35217573, PMCID: PMC8883256, DOI: 10.1136/jitc-2021-003026.
• Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)Mahdi H, Hafez N, Doroshow D, Sohal D, Keedy V, T. K, LoRusso P, Jürgensmeier J, Avedissian M, Sklar J, Glover C, Felicetti B, Dean E, Mortimer P, Shapiro GI, Eder JP. Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations). JCO Precision Oncology 2021, 5: 1432-1442. PMID: 34527850, PMCID: PMC8437220, DOI: 10.1200/po.20.00439.
• Phase 1 Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844)Roussos Torres ET, Rafie C, Wang C, Lim D, Brufsky A, LoRusso P, Eder JP, Chung V, Downs M, Geare M, Piekarz R, Streicher H, Anforth L, Rudek MA, Zhu Q, Besharati S, Cimino-Mathews A, Anders RA, Stearns V, Jaffee EM, Connolly RM. Phase 1 Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844). Clinical Cancer Research 2021, 27: clincanres.5017.2021. PMID: 34135021, PMCID: PMC8563383, DOI: 10.1158/1078-0432.ccr-20-5017.
• Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trialLoRusso PM, Sekulic A, Sosman JA, Liang WS, Carpten J, Craig DW, Solit DB, Bryce AH, Kiefer JA, Aldrich J, Nasser S, Halperin R, Byron SA, Pilat MJ, Boerner SA, Durecki D, Hendricks WPD, Enriquez D, Izatt T, Keats J, Legendre C, Markovic SN, Weise A, Naveed F, Schmidt J, Basu GD, Sekar S, Adkins J, Tassone E, Sivaprakasam K, Zismann V, Calvert VS, Petricoin EF, Fecher LA, Lao C, Eder JP, Vogelzang NJ, Perlmutter J, Gorman M, Manica B, Fox L, Schork N, Zelterman D, DeVeaux M, Joseph RW, Cowey CL, Trent JM. Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial. PLOS ONE 2021, 16: e0248097. PMID: 33826614, PMCID: PMC8026051, DOI: 10.1371/journal.pone.0248097.
• Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment planGibson JA, Finberg KE, Nalbantoglu I, Cecchini M, Ganzak A, Walther Z, Sklar JL, Eder JP, Goldberg SB. Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan. The Lancet Oncology 2021, 22: 306-307. PMID: 33662283, DOI: 10.1016/s1470-2045(20)30683-5.
• Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal SarcomasEder JP, Doroshow DB, T. K, Keedy VL, Sklar JS, Glazer P, Bindra R, Shapiro GI. Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas. JCO Precision Oncology 2021, 5: 466-472. PMID: 34994649, PMCID: PMC9848565, DOI: 10.1200/po.20.00247.
• A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphomaShapiro GI, LoRusso P, Dowlati A, T. Do K, Jacobson CA, Vaishampayan U, Weise A, Caimi PF, Eder JP, French CA, Labriola-Tompkins E, Boisserie F, Pierceall WE, Zhi J, Passe S, DeMario M, Kornacker M, Armand P. A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. British Journal Of Cancer 2020, 124: 744-753. PMID: 33311588, PMCID: PMC7884382, DOI: 10.1038/s41416-020-01180-1.
• Skin puckering and edema during durvalumab therapyOlamiju B, Odell I, Panse G, Eder JP, Leventhal JS. Skin puckering and edema during durvalumab therapy. JAAD Case Reports 2020, 7: 110-112. PMID: 33364282, PMCID: PMC7750709, DOI: 10.1016/j.jdcr.2020.11.019.
• Tissue/Site-Agnostic Study of Ribociclib for Tumors With Cyclin D-CDK4/6 Pathway Genomic Alterations: A Phase II, Open-Label, Single-Arm Basket Study.Peguero J, Sohal DPS, O'Neil BH, Safran H, Kelly K, Grilley-Olson JE, Subbiah V, Nadauld L, Purkayastha D, Stealey E, Ricart AD, Kang BP, Eder JP. Tissue/Site-Agnostic Study of Ribociclib for Tumors With Cyclin D-CDK4/6 Pathway Genomic Alterations: A Phase II, Open-Label, Single-Arm Basket Study. JCO Precision Oncology 2019, 3: 1-10. PMID: 35100715, DOI: 10.1200/PO.18.00383.
• New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial DesignsJürgensmeier JM, Eder JP, Herbst RS. New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs. Clinical Cancer Research 2014, 20: 4425-4435. PMID: 25183480, PMCID: PMC5369358, DOI: 10.1158/1078-0432.ccr-13-0753.
• Proteasome Inhibition With Bortezomib (PS-341): A Phase I Study With Pharmacodynamic End Points Using a Day 1 and Day 4 Schedule in a 14-Day CycleHamilton AL, Eder JP, Pavlick AC, Clark JW, Liebes L, Garcia-Carbonero R, Chachoua A, Ryan DP, Soma V, Farrell K, Kinchla N, Boyden J, Yee H, Zeleniuch-Jacquotte A, Wright J, Elliott P, Adams J, Muggia FM. Proteasome Inhibition With Bortezomib (PS-341): A Phase I Study With Pharmacodynamic End Points Using a Day 1 and Day 4 Schedule in a 14-Day Cycle. Journal Of Clinical Oncology 2005, 23: 6107-6116. PMID: 16135477, DOI: 10.1200/jco.2005.01.136.
• A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours.Penson RT, Seiden MV, Matulonis UA, Appleman LJ, Fuller AF, Goodman A, Campos SM, Clark JW, Roche M, Eder JP. A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours. British Journal Of Cancer 2005, 93: 54-9. PMID: 15986034, PMCID: PMC2361482, DOI: 10.1038/sj.bjc.6602671.
• Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies.Bunnell CA, Supko JG, Eder JP, Clark JW, Lynch TJ, Kufe DW, Shulman LN. Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies. Cancer Chemotherapy And Pharmacology 2001, 48: 347-55. PMID: 11761451, DOI: 10.1007/s002800100319.
• Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies.Villalona-Calero MA, Eder JP, Toppmeyer DL, Allen LF, Fram R, Velagapudi R, Myers M, Amato A, Kagen-Hallet K, Razvillas B, Kufe DW, Von Hoff DD, Rowinsky EK. Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2001, 19: 857-69. PMID: 11157040, DOI: 10.1200/JCO.2001.19.3.857.
• Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.Ryan DP, Supko JG, Eder JP, Seiden MV, Demetri G, Lynch TJ, Fischman AJ, Davis J, Jimeno J, Clark JW. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2001, 7: 231-42. PMID: 11234874.
• A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY, Panicali D, Schlom J, Kufe DW. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2000, 6: 1632-8. PMID: 10815880.
• A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion.Supko JG, Lynch TJ, Clark JW, Fram R, Allen LF, Velagapudi R, Kufe DW, Eder JP. A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion. Cancer Chemotherapy And Pharmacology 2000, 46: 319-28. PMID: 11052630, DOI: 10.1007/s002800000152.
• Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion.Eder JP, Supko JG, Lynch T, Bryant M, Vosburgh E, Shulman LN, Xu G, Kufe DW. Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 1998, 4: 317-24. PMID: 9516917.
• Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo.Eder JP, Chan V, Wong J, Wong YW, Ara G, Northey D, Rizvi N, Teicher BA. Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo. Cancer Chemotherapy And Pharmacology 1998, 42: 327-35. PMID: 9744779, DOI: 10.1007/s002800050825.
• High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.Wheeler C, Eickhoff C, Elias A, Ibrahim J, Ayash L, McCauley M, Mauch P, Schwartz G, Eder JP, Mazanet R, Ferrara J, Rimm IJ, Guinan E, Bierer B, Gilliland G, Churchill WH, Ault K, Parsons S, Antman K, Schnipper L, Tepler I, Gaynes L, Frei E, Kadin M, Antin J. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. Biology Of Blood And Marrow Transplantation : Journal Of The American Society For Blood And Marrow Transplantation 1997, 3: 98-106. PMID: 9267670.
• DNA topoisomerase II alpha expression is associated with alkylating agent resistance.Eder JP, Chan VT, Ng SW, Rizvi NA, Zacharoulis S, Teicher BA, Schnipper LE. DNA topoisomerase II alpha expression is associated with alkylating agent resistance. Cancer Research 1995, 55: 6109-16. PMID: 8521401.
• Molecular cloning and characterization of the promoter for the Chinese hamster DNA topoisomerase II alpha gene.Ng SW, Eder JP, Schnipper LE, Chan VT. Molecular cloning and characterization of the promoter for the Chinese hamster DNA topoisomerase II alpha gene. The Journal Of Biological Chemistry 1995, 270: 25850-8. PMID: 7592770, DOI: 10.1074/jbc.270.43.25850.
• Conditional expression of wild-type topoisomerase II complements a mutant enzyme in mammalian cells.Eder JP, Chan VT, Niemierko E, Teicher BA, Schnipper LE. Conditional expression of wild-type topoisomerase II complements a mutant enzyme in mammalian cells. The Journal Of Biological Chemistry 1993, 268: 13844-9. PMID: 8390979.
• Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide.Wheeler C, Strawderman M, Ayash L, Churchill WH, Bierer BE, Elias A, Gilliland DG, Antman K, Guinan EC, Eder JP. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1993, 11: 1085-91. PMID: 8099120, DOI: 10.1200/JCO.1993.11.6.1085.
• Intensive combined modality therapy for limited-stage small-cell lung cancer.Elias AD, Ayash L, Frei E, Skarin AT, Hunt M, Wheeler C, Schwartz G, Mazanet R, Tepler I, Eder JP. Intensive combined modality therapy for limited-stage small-cell lung cancer. Journal Of The National Cancer Institute 1993, 85: 559-66. PMID: 8384264, DOI: 10.1093/jnci/85.7.559.
• Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese hamster ovary cell line.Chan VT, Ng SW, Eder JP, Schnipper LE. Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese hamster ovary cell line. The Journal Of Biological Chemistry 1993, 268: 2160-5. PMID: 8380592.
• Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.Schwartz GN, Teicher BA, Eder JP, Korbut T, Holden SA, Ara G, Herman TS. Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine. Cancer Chemotherapy And Pharmacology 1993, 32: 455-62. PMID: 8258194, DOI: 10.1007/BF00685890.
• Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid tumors with autologous marrow transplant: an analysis of four chemotherapy regimens.Seiden MV, Elias A, Ayash L, Hunt M, Eder JP, Schnipper LE, Frei E, Antman KH. Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid tumors with autologous marrow transplant: an analysis of four chemotherapy regimens. Bone Marrow Transplantation 1992, 10: 57-63. PMID: 1515880.
• Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response.Ayash LJ, Wright JE, Tretyakov O, Gonin R, Elias A, Wheeler C, Eder JP, Rosowsky A, Antman K, Frei E. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1992, 10: 995-1000. PMID: 1588381, DOI: 10.1200/JCO.1992.10.6.995.
• A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy.Antman K, Ayash L, Elias A, Wheeler C, Hunt M, Eder JP, Teicher BA, Critchlow J, Bibbo J, Schnipper LE. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1992, 10: 102-10. PMID: 1727912, DOI: 10.1200/JCO.1992.10.1.102.
• Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.Teicher BA, Herman TS, Tanaka J, Eder JP, Holden SA, Bubley G, Coleman CN, Frei E. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma. Cancer Research 1991, 51: 1086-91. PMID: 1825474.
• A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.Elias AD, Ayash LJ, Eder JP, Wheeler C, Deary J, Weissman L, Schryber S, Hunt M, Critchlow J, Schnipper L. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1991, 9: 320-7. PMID: 1846407, DOI: 10.1200/JCO.1991.9.2.320.
• A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity.Eder JP, Wheeler CA, Teicher BA, Schnipper LE. A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity. Cancer Research 1991, 51: 510-3. PMID: 1985770.
• Escalating doses of carboplatin with high-dose ifosfamide using autologous bone marrow as support: a phase I study.Elias AD, Ayash LJ, Eder JP, Wheeler C, Deary J, Weissman L, Hunt M, Critchlow J, Schnipper L, Frei E. Escalating doses of carboplatin with high-dose ifosfamide using autologous bone marrow as support: a phase I study. Journal Of Cancer Research And Clinical Oncology 1991, 117 Suppl 4: S208-13. PMID: 1795009, DOI: 10.1007/BF01613229.
• A phase I trial of continuous-infusion cyclophosphamide in refractory cancer patients.Eder JP, Elias AD, Ayash L, Wheeler CA, Shea TC, Schnipper LE, Frei E, Antman KH. A phase I trial of continuous-infusion cyclophosphamide in refractory cancer patients. Cancer Chemotherapy And Pharmacology 1991, 29: 61-5. PMID: 1742850, DOI: 10.1007/BF00686337.
• Erythropoietin gene regulation: from the laboratory to the bedside.Goldberg MA, Gaut CC, Schapira L, Antin JH, Ransil BJ, Antman KH, Eder JP, McGarigle CJ, Bunn HF. Erythropoietin gene regulation: from the laboratory to the bedside. Contributions To Nephrology 1991, 88: 35-45; discussion 46-7. PMID: 2040197, DOI: 10.1159/000419514.
• Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy.Schapira L, Antin JH, Ransil BJ, Antman KH, Eder JP, McGarigle CJ, Goldberg MA. Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood 1990, 76: 2354-9. PMID: 2257306.
• Phase I trial of escalating pentoxifylline dose with constant dose thiotepa.Dezube BJ, Eder JP, Pardee AB. Phase I trial of escalating pentoxifylline dose with constant dose thiotepa. Cancer Research 1990, 50: 6806-10. PMID: 2119882.
• Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas.Ayash LJ, Hunt M, Antman K, Nadler L, Wheeler C, Takvorian T, Elias A, Antin JH, Greenough T, Eder JP. Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1990, 8: 1699-706. PMID: 2213105, DOI: 10.1200/JCO.1990.8.10.1699.
• A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients.Eder JP, Elias A, Shea TC, Schryber SM, Teicher BA, Hunt M, Burke J, Siegel R, Schnipper LE, Frei E. A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1990, 8: 1239-45. PMID: 2162912, DOI: 10.1200/JCO.1990.8.7.1239.
• High-dose thiotepa alone and in combination regimens with bone marrow support.Antman K, Eder JP, Elias A, Ayash L, Shea TC, Weissman L, Critchlow J, Schryber SM, Begg C, Teicher BA. High-dose thiotepa alone and in combination regimens with bone marrow support. Seminars In Oncology 1990, 17: 33-8. PMID: 2106166.
• Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination.Teicher BA, Holden SA, Eder JP, Herman TS, Antman KH, Frei E. Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination. Seminars In Oncology 1990, 17: 18-32. PMID: 2106164.
• High-dose ifosfamide with mesna uroprotection: a phase I study.Elias AD, Eder JP, Shea T, Begg CB, Frei E, Antman KH. High-dose ifosfamide with mesna uroprotection: a phase I study. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1990, 8: 170-8. PMID: 2104923, DOI: 10.1200/JCO.1990.8.1.170.
• Ability of four potential topoisomerase II inhibitors to enhance the cytotoxicity of cis-diamminedichloroplatinum (II) in Chinese hamster ovary cells and in an epipodophyllotoxin-resistant subline.Eder JP, Teicher BA, Holden SA, Senator L, Cathcart KN, Schnipper LE. Ability of four potential topoisomerase II inhibitors to enhance the cytotoxicity of cis-diamminedichloroplatinum (II) in Chinese hamster ovary cells and in an epipodophyllotoxin-resistant subline. Cancer Chemotherapy And Pharmacology 1990, 26: 423-8. PMID: 2171796, DOI: 10.1007/BF02994093.
• Endogenous digoxin-like immunoreactive factor and digitalis-like factor associated with the hypertension of patients receiving multiple alkylating agents as part of autologous bone marrow transplantation.Graves SW, Eder JP, Schryber SM, Sharma K, Brena A, Antman KH, Peters WP. Endogenous digoxin-like immunoreactive factor and digitalis-like factor associated with the hypertension of patients receiving multiple alkylating agents as part of autologous bone marrow transplantation. Clinical Science (London, England : 1979) 1989, 77: 501-7. PMID: 2555106, DOI: 10.1042/cs0770501.
• Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.Teicher BA, Holden SA, Eder JP, Brann TW, Jones SM, Frei E. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. Cancer Research 1989, 49: 5994-8. PMID: 2790813.
• A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support.Shea TC, Flaherty M, Elias A, Eder JP, Antman K, Begg C, Schnipper L, Frei E, Henner WD. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. Journal Of Clinical Oncology 1989, 7: 651-61. PMID: 2651580, DOI: 10.1200/jco.1989.7.5.651.
• Effect of novobiocin on the antitumor activity and tumor cell and bone marrow survivals of three alkylating agents.Eder JP, Teicher BA, Holden SA, Cathcart KN, Schnipper LE, Frei E. Effect of novobiocin on the antitumor activity and tumor cell and bone marrow survivals of three alkylating agents. Cancer Research 1989, 49: 595-8. PMID: 2910481.
• Influence of scheduling on two-drug combinations of alkylating agents in vivo.Teicher BA, Holden SA, Jones SM, Eder JP, Herman TS. Influence of scheduling on two-drug combinations of alkylating agents in vivo. Cancer Chemotherapy And Pharmacology 1989, 25: 161-6. PMID: 2513139, DOI: 10.1007/BF00689576.
• Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors.Eder JP, Antman K, Elias A, Shea TC, Teicher B, Henner WD, Schryber SM, Holden S, Finberg R, Chritchlow J. Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors. Journal Of The National Cancer Institute 1988, 80: 1221-6. PMID: 3138431, DOI: 10.1093/jnci/80.15.1221.
• Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support.Shea TC, Antman KH, Eder JP, Elias A, Peters WP, Schryber S, Henner WD, Schoenfeld DA, Schnipper LE, Frei E. Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support. JAMA Dermatology 1988, 124: 878-84. PMID: 3288124, DOI: 10.1001/archderm.124.6.878.
• Pharmacokinetics of continuous-infusion high-dose thiotepa.Henner WD, Shea TC, Furlong EA, Flaherty MD, Eder JP, Elias A, Begg C, Antman K. Pharmacokinetics of continuous-infusion high-dose thiotepa. Cancer Treatment Reports 1987, 71: 1043-7. PMID: 3119200.
• Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model.Eder JP, Teicher BA, Holden SA, Cathcart KN, Schnipper LE. Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model. The Journal Of Clinical Investigation 1987, 79: 1524-8. PMID: 3033027, PMCID: PMC424429, DOI: 10.1172/JCI112983.
• High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience.Antman K, Eder JP, Elias A, Shea T, Peters WP, Andersen J, Schryber S, Henner WD, Finberg R, Wilmore D. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience. Journal Of The National Cancer Institute 1987, 71: 119-25. PMID: 3542208.
• High-dose chemotherapy with bone marrow support for solid tumors.Antman K, Eder JP, Frei E. High-dose chemotherapy with bone marrow support for solid tumors. Important Advances In Oncology 1987, 221-35. PMID: 2841230.
• High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer.Eder JP, Antman K, Peters W, Henner WD, Elias A, Shea T, Schryber S, Andersen J, Come S, Schnipper L. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. Journal Of Clinical Oncology 1986, 4: 1592-7. PMID: 3534155, DOI: 10.1200/jco.1986.4.11.1592.
• Prediction of the optimal timing of bone marrow reinfusion after high dose chemotherapy.Eder JP, Bast RC, Peters WP, Henner D, Sanchez E, Schryber S, Frei E, Schnipper LE. Prediction of the optimal timing of bone marrow reinfusion after high dose chemotherapy. Cancer Research 1986, 46: 4496-9. PMID: 3524814.
• Pharmacokinetics and immediate effects of high-dose carmustine in man.Henner WD, Peters WP, Eder JP, Antman K, Schnipper L, Frei E. Pharmacokinetics and immediate effects of high-dose carmustine in man. Cancer Treatment Reports 1986, 70: 877-80. PMID: 3719578.
• High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial.Peters WP, Eder JP, Henner WD, Schryber S, Wilmore D, Finberg R, Schoenfeld D, Bast R, Gargone B, Antman K. High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 1986, 4: 646-54. PMID: 3517240, DOI: 10.1200/JCO.1986.4.5.646.